| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T508 |
0-148 |
Sentence |
denotes |
It an orally bioavailable, small molecule, reversible covalent inhibitor of calpains, non-lysosomal cysteine proteases, with anti-fibrotic activity. |
| T509 |
149-320 |
Sentence |
denotes |
BLD-2660 exhibited potent and selective inhibition of calpains 1,2, and 9 and thus was found to be efficacious in multiple animal fibrosis models of skin, liver, and lung. |
| T510 |
321-386 |
Sentence |
denotes |
It exhibited high selectivity against related cysteine proteases. |
| T511 |
387-490 |
Sentence |
denotes |
Earlier, several calpain inhibitors were found to reduce the viral replication of SARS-CoV-1 [232,233]. |
| T512 |
491-662 |
Sentence |
denotes |
The antiviral activity by calpain inhibition was also verified using siRNA to selectively silence expression of the calpain 2 isoform in SARS-CoV infected cells [232,233]. |
| T513 |
663-782 |
Sentence |
denotes |
Undisclosed inhibitors by the developing company were found to reduce SARS-CoV-2 replication in Vero cell-based assays. |
| T514 |
783-963 |
Sentence |
denotes |
Furthermore, in preclinical animal models of lung injury and fibrosis, BLD-2660 was shown to reduce the expression/production of IL-6 in injured lungs and to reduce fibrosis [234]. |
| T515 |
964-1222 |
Sentence |
denotes |
Owing to the antiviral and anti-inflammatory activities of BLD-2660, it has been advanced to a phase 2, randomized, double-blind, placebo-controlled study to evaluate its safety and antiviral activity in COVID-19 hospitalized subjects (NCT04334460; n = 120). |
